IL-6 and MMP-7 biomarkers in pediatric immune-mediated interstitial lung disease
Part of Lungs & breathing clinical trials.
This study looks at whether two proteins in the blood (IL-6 and MMP-7) can help diagnose and predict the course of a rare lung condition in children that is caused by immune system problems. If these proteins are helpful, they might lead to simpler tests and better monitoring for children with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 18 years old
- Your child must have a diagnosis of an immune-related lung disease (like from arthritis, lupus, or another autoimmune condition)
- Your child must have a confirmed diagnosis of interstitial lung disease (a lung condition causing inflammation or scarring)
- We need to be able to get a blood sample from your child to measure IL-6 and MMP-7
- Your child must not have lung disease from an infection, medication, or other non-immune cause
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This study looks at two substances in saliva and lung fluid—called IL-6 and TNF-α—in children with severe lung failure (ARDS) who are on a breathing machine. Measuring these markers may help doctors better understand the condition and guide treatment.
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
This study looks at a type of white blood cell called eosinophils in people with interstitial lung disease (a group of conditions that cause lung scarring). It aims to understand if eosinophil levels are linked to the disease, which might help improve future treatments.
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
Hear when a new Pediatric Immune Mediated Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.